Neurogene (NGNE) Preferred Dividend Payments (2013 - 2014)
Neurogene (NGNE) posted Preferred Dividend Payments of $6650.0 for Q2 2014, down 65.98% on a QoQ basis from $19550.0 in Q1 2014, and down 84.22% year-over-year from $42130.0 in Q2 2013.
Neurogene (NGNE) Preferred Dividend Payments (2013 - 2014) Analysis & Trends
Neurogene's Preferred Dividend Payments history runs 2 years deep, the most recent figure standing at $6650.0 for Q2 2014.
- Quarterly Preferred Dividend Payments fell 84.22% year-over-year to $6650.0 in Q2 2014, while the trailing twelve-month figure through Jun 2014 was $112637.0 (changed N/A YoY) and the FY2013 annual result came in at $123074.0, down 27.05% from the prior year.
- Preferred Dividend Payments was $6650.0 for Q2 2014 at Neurogene, down from $19550.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $44307.0 in Q1 2013 and bottomed at $6650.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 6,650.00 |
| Mar 31, 2014 | 19,550.00 |
| Jun 30, 2013 | 42,130.00 |
| Mar 31, 2013 | 44,307.00 |